Insulin Glargine-aglr Injection — FDA Drug Shortage

To Be Discontinued — Eli Lilly And Co.

The FDA lists a drug shortage record for Insulin Glargine-aglr Injection (injection) from Eli Lilly And Co. with status To Be Discontinued. The shortage was first posted on Sep 1, 2026.

Shortage details

Status
To Be Discontinued
Company
Eli Lilly And Co.
Package NDC
0002-8980-05
Dosage Form
Injection
Presentation
Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
Initial Posting
Sep 1, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.